JP2023100870A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023100870A5 JP2023100870A5 JP2023076856A JP2023076856A JP2023100870A5 JP 2023100870 A5 JP2023100870 A5 JP 2023100870A5 JP 2023076856 A JP2023076856 A JP 2023076856A JP 2023076856 A JP2023076856 A JP 2023076856A JP 2023100870 A5 JP2023100870 A5 JP 2023100870A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- urolithin
- composition
- salt
- muscle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 27
- RIUPLDUFZCXCHM-UHFFFAOYSA-N Urolithin A Chemical compound OC1=CC=C2C3=CC=C(O)C=C3OC(=O)C2=C1 RIUPLDUFZCXCHM-UHFFFAOYSA-N 0.000 claims 24
- 150000003839 salts Chemical class 0.000 claims 11
- 210000003205 muscle Anatomy 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000002207 metabolite Substances 0.000 claims 4
- 230000036470 plasma concentration Effects 0.000 claims 4
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims 3
- 229960004203 carnitine Drugs 0.000 claims 3
- 235000015872 dietary supplement Nutrition 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 230000008437 mitochondrial biogenesis Effects 0.000 claims 3
- 230000004220 muscle function Effects 0.000 claims 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 3
- 230000002715 bioenergetic effect Effects 0.000 claims 2
- 230000006806 disease prevention Effects 0.000 claims 2
- 230000002438 mitochondrial effect Effects 0.000 claims 2
- 238000011084 recovery Methods 0.000 claims 2
- 206010006895 Cachexia Diseases 0.000 claims 1
- 208000036119 Frailty Diseases 0.000 claims 1
- 208000029578 Muscle disease Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 206010003549 asthenia Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 230000000378 dietary effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 235000012041 food component Nutrition 0.000 claims 1
- 239000005417 food ingredient Substances 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- 230000036284 oxygen consumption Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000001076 sarcopenia Diseases 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1703736.7A GB201703736D0 (en) | 2017-03-08 | 2017-03-08 | Methods for improving mitophagy in subjects |
| GB1703736.7 | 2017-03-08 | ||
| GB1706596.2 | 2017-04-25 | ||
| GBGB1706596.2A GB201706596D0 (en) | 2017-04-25 | 2017-04-25 | Methods for improving mitophagy in subjects |
| GB1707863.5 | 2017-05-16 | ||
| GBGB1707863.5A GB201707863D0 (en) | 2017-05-16 | 2017-05-16 | Methods for improving mitophagy in subjects |
| JP2019548677A JP7761372B2 (ja) | 2017-03-08 | 2018-03-08 | 対象におけるマイトファジーを改善するための方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019548677A Division JP7761372B2 (ja) | 2017-03-08 | 2018-03-08 | 対象におけるマイトファジーを改善するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023100870A JP2023100870A (ja) | 2023-07-19 |
| JP2023100870A5 true JP2023100870A5 (https=) | 2024-03-12 |
Family
ID=61691937
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019548677A Active JP7761372B2 (ja) | 2017-03-08 | 2018-03-08 | 対象におけるマイトファジーを改善するための方法 |
| JP2023076856A Pending JP2023100870A (ja) | 2017-03-08 | 2023-05-08 | 対象におけるマイトファジーを改善するための方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019548677A Active JP7761372B2 (ja) | 2017-03-08 | 2018-03-08 | 対象におけるマイトファジーを改善するための方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US11969408B2 (https=) |
| EP (2) | EP3592425A1 (https=) |
| JP (2) | JP7761372B2 (https=) |
| WO (1) | WO2018162651A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK4233858T3 (da) | 2012-06-27 | 2025-05-12 | Amazentis Sa | Forbedring af autofagi eller forøgelse af levetiden ved indgivelse af urolithiner eller forstadier til disse |
| US20180256538A1 (en) * | 2017-03-08 | 2018-09-13 | Amazentis Sa | Method for improving mitophagy in subjects |
| US20180256471A1 (en) * | 2017-03-08 | 2018-09-13 | Amazentis Sa | Skin Treatment Methods |
| GB201916046D0 (en) * | 2019-11-04 | 2019-12-18 | Amazentis Sa | Diagnostic method |
| CA3206062A1 (en) | 2021-01-27 | 2022-08-04 | Said Oumouch | Urolithin derivatives and methods of use thereof |
| JP2022185501A (ja) * | 2021-06-02 | 2022-12-14 | 株式会社ダイセル | 閉経後の女性の筋肉の重量を増加させるための組成物 |
| EP4452259A1 (en) * | 2021-12-20 | 2024-10-30 | Société des Produits Nestlé S.A. | Compositions comprising urolithin for treating muscle decline and a kidney dysfunction |
| JP2025510123A (ja) | 2022-03-22 | 2025-04-14 | アマゼンティス エスアー | 組成物 |
| CA3258478A1 (en) * | 2022-06-06 | 2023-12-14 | Amazentis Sa | Urolithines to improve heart function and health |
| AU2024279527A1 (en) * | 2023-05-26 | 2026-01-15 | Amazentis Sa | Urolithin for improving performance in elite and sub-elite athletes |
| GB202308224D0 (en) | 2023-06-01 | 2023-07-19 | Amazentis Sa | Formulation |
| WO2024252410A1 (en) * | 2023-06-09 | 2024-12-12 | Celagenex Research (India) Pvt. Ltd. | Synergistic bioactive composition for enhancing activity of pink1/parkin pathway |
| GB202319994D0 (en) | 2023-12-22 | 2024-02-07 | Amazentis Sa | Compositions for use |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02304080A (ja) | 1989-05-17 | 1990-12-17 | Toyo Pharma- Kk | ６Ｈ―ジベンゾ［ｂ，ｄ］ピラン―６―オン誘導体，その製法及び用途 |
| KR20000019718A (ko) | 1998-09-15 | 2000-04-15 | 박호군 | 탄닌 또는 탄닌 유래 페놀성 화합물을 포함하는 동맥경화증, 고지혈증 및 간질환의 예방 및 치료용 조성물 |
| US20030078212A1 (en) | 1998-10-30 | 2003-04-24 | Jia-He Li | Pharmaceutical compositions containing poly(adp-ribose) glycohydrolase inhibitors and methods of using the same |
| US7727563B2 (en) | 1999-04-19 | 2010-06-01 | Pom Wonderful, Llc | Methods of using pomegranate extracts for treating diabetes related atherosclerotic complications in humans |
| US7611738B2 (en) | 2005-05-24 | 2009-11-03 | Pom Wonderful, Llc | Processes for extracting phytochemicals from pomegranate solids and compositions and methods of use thereof |
| US20010047032A1 (en) | 1999-12-30 | 2001-11-29 | Castillo Gerardo M. | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases |
| US6440436B1 (en) | 2001-05-18 | 2002-08-27 | Natreon Inc. | Process for preparing purified shilajit composition from native shilajit |
| US20080039179A1 (en) | 2001-06-27 | 2008-02-14 | Seelig Jerald C | Gaming display with moveable indicator and methods of use |
| WO2004073612A2 (en) * | 2003-02-13 | 2004-09-02 | Merck & Co. Inc. | Estrogen receptor modulators |
| US20050171079A1 (en) | 2004-02-04 | 2005-08-04 | Schrimpf Michael R. | Amino-substituted tricyclic derivatives and methods of use |
| US7365193B2 (en) | 2004-02-04 | 2008-04-29 | Abbott Laboratories | Amino-substituted tricyclic derivatives and methods of use |
| ES2543981T3 (es) | 2004-03-24 | 2015-08-26 | The Regents Of The University Of California | Purificaciones de elagitaninos |
| US20050282781A1 (en) | 2004-06-18 | 2005-12-22 | Shibnath Ghosal | Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids |
| US20060257337A1 (en) | 2005-04-28 | 2006-11-16 | David Sherris | Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis |
| BRPI0708318A2 (pt) | 2006-02-28 | 2011-05-24 | Paloma Pharmaceuticals, Inc. | composições e uso de compostos para tratar doenças caracterizadas por proliferação celular e angiogênese |
| WO2007127263A2 (en) | 2006-04-26 | 2007-11-08 | The Regents Of The University Of California | Therapeutic uses of urolithins |
| US8894993B2 (en) | 2006-08-04 | 2014-11-25 | Natreon Inc. | Mitochondria-targeted antioxidants |
| US8017147B2 (en) | 2008-04-07 | 2011-09-13 | Mazed Mohammad A | Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance |
| US8367072B2 (en) | 2006-12-08 | 2013-02-05 | Polifenoles Naturales, S.L. | Composition for treating obesity and method of using the same |
| US7972633B2 (en) | 2007-02-07 | 2011-07-05 | Applied Cognitive Sciences, LLC | Nutritional supplements for healthy memory and mental function |
| WO2008139123A2 (fr) | 2007-05-11 | 2008-11-20 | Galderma Research & Development | Preparations pharmaceutiques ou cosmetiques pour application topique et/ou parenterale, leurs procedes de preparation, et leurs utilisations |
| EP2033526A1 (en) | 2007-09-07 | 2009-03-11 | Probelte Pharma, S.A. | Nutritional products comprising pomegranate extracts containing ellagitannins and their use |
| US20110021618A1 (en) | 2008-03-25 | 2011-01-27 | Paloma Pharmaceuticals, Inc. | Methods of treating fibrotic disorders |
| US7927633B2 (en) | 2008-03-28 | 2011-04-19 | Janiece Diane Swilling | Adaptogenic tea |
| WO2009137859A1 (en) * | 2008-05-15 | 2009-11-19 | Alois Jungbauer | Compounds for the treatment of metabolic syndrome and insulin resistance |
| WO2009153652A2 (en) | 2008-06-19 | 2009-12-23 | Avesthagen Limited | An extract and a process thereof (pomplex) |
| US20100004334A1 (en) | 2008-07-01 | 2010-01-07 | Mead Johnson Nutrition Company | Nutritional Compositions Containing Punicalagins |
| CN101301319A (zh) | 2008-07-09 | 2008-11-12 | 中国科学院新疆理化技术研究所 | 石榴花多酚的制备方法及其应用 |
| US20100055247A1 (en) | 2008-08-29 | 2010-03-04 | Tirrito Salvatore J | Nutritional Compositions for Athletes |
| JP5385686B2 (ja) | 2009-06-05 | 2014-01-08 | サントリーホールディングス株式会社 | 血小板凝集抑制剤 |
| WO2011011721A2 (en) | 2009-07-24 | 2011-01-27 | Amazentis Sa | Compounds, compositions and methods for protecting brain health in neurodegenerative disorders |
| JP6054301B2 (ja) | 2010-12-23 | 2017-01-11 | アマゼンティス エスアーＡｍａｚｅｎｔｉｓ Ｓａ | ミトコンドリア機能向上と、神経変性疾患および認知障害治療とのための組成物および方法 |
| WO2012113835A1 (en) | 2011-02-22 | 2012-08-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | C-glucosidic ellagitannin compounds for use for altering the supramolecular arrangement of actin and for the treatment of osteoporosis, cancer, bacterial infection and viral infection |
| DK4233858T3 (da) | 2012-06-27 | 2025-05-12 | Amazentis Sa | Forbedring af autofagi eller forøgelse af levetiden ved indgivelse af urolithiner eller forstadier til disse |
| GB201323008D0 (en) | 2013-12-24 | 2014-02-12 | Amazentis As | Compounds and uses thereof |
| US20180256538A1 (en) * | 2017-03-08 | 2018-09-13 | Amazentis Sa | Method for improving mitophagy in subjects |
| US20180256471A1 (en) * | 2017-03-08 | 2018-09-13 | Amazentis Sa | Skin Treatment Methods |
-
2018
- 2018-03-08 JP JP2019548677A patent/JP7761372B2/ja active Active
- 2018-03-08 EP EP18712107.4A patent/EP3592425A1/en active Pending
- 2018-03-08 US US15/915,842 patent/US11969408B2/en active Active
- 2018-03-08 EP EP25165114.7A patent/EP4566601A3/en active Pending
- 2018-03-08 WO PCT/EP2018/055790 patent/WO2018162651A1/en not_active Ceased
-
2023
- 2023-05-08 JP JP2023076856A patent/JP2023100870A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023100869A5 (https=) | ||
| JP2023100870A5 (https=) | ||
| ES3013603T3 (en) | A composition for weight loss or weight management comprising beta-hydroxybutyrate and cannabidiol | |
| US10292952B2 (en) | Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis | |
| KR100545630B1 (ko) | 필수 지방산과 생물활성 이황화물을 함유하는 치료 및식이요법 조성물 | |
| US6346519B1 (en) | Method and composition for treating arthritis | |
| JPS61277618A (ja) | 自閉症治療剤 | |
| JP2020514338A5 (https=) | ||
| JP2020510678A5 (https=) | ||
| PT1187603E (pt) | ''terapia de associação para promover a perda de peso e o tratamento da obesidade'' | |
| CN110730659B (zh) | 用于提高l-dopa治疗功效的组合物 | |
| AU2012272731A1 (en) | Compositions and methods for treatment of chronic fatigue | |
| US20100179089A1 (en) | Compositions and Methods to Manage the Inflammatory Basis of Chronic Disease Conditions and Maintain an Optimal Immune Response in Elderly | |
| AU2012382949A1 (en) | Compositions and methods for treatment of neuropsychological deficits | |
| US20200360322A1 (en) | Formulations and dosage forms for enhancing performance or recovery from stress | |
| US8435963B2 (en) | Weight loss compositions and uses thereof | |
| JP2023535067A (ja) | ヒトにおける呼吸器疾患の治療及び／又は予防のためのβ－ヒドロキシブチレート及び関連化合物の投与 | |
| EP1498119B1 (en) | Use of conjugated linoleic acid for treating colds | |
| US20100255088A1 (en) | Method for delivering a combination of resveratrol and aspirin for use in treatment and prevention of vascular disease | |
| CN111000862A (zh) | 靶向线粒体逆转早早期癌症的药物组合物及其应用 | |
| JP2026501988A (ja) | ウロチリンとケトン体との組み合わせ | |
| KR101086895B1 (ko) | 시부트라민 및 티옥트산을 포함하는 약제학적 조성물 | |
| WO2019117820A1 (en) | L-enantiomer 2-ethyl-6-methyl-3-hydroxypyridinium l-hydroxybutandioate with cerebroprotective, hepatoprotective, lipid-regulating, anti-ischemic and neurotropic activities | |
| JP2022071083A (ja) | うつ病を予防または治療するための安息香酸またはその塩および誘導体 | |
| van Huysduynen | If channels: a new target for the treatment of stable angina: Munich, 31 August 2004 |